Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS: EMPA treatment resulted in a placebo-corrected absolute change of −1.8% (95% CI −3.4, −0.2; P = 0.02) and relative change in LFC of −22% (−36, −7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change −2.5 kg [−3.7, −1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (−74 mol/L [−108, −42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Notably, weight loss-mediated improvement of MASLD-related steatosis did not necessarily depend on normalization of glycemia in RCTs with caloric restriction or sodium-glucose co-transporter 2 inhibitor (SGLT2I) treatment [97][98][99].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“whereas both dapagliflozin and empagliflozin were able to reduce liver lipid content in people with type 2 diabetes with (dapagliflozin [153,154]) or both with and without MASLD (empagliflozin [98]).”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Further, in another RCT, empagliflozin led to a placebocorrected 2.3-fold greater reduction in liver lipid content and a 36 % increase in plasma adiponectin levels in people with type 2 diabetes and short diabetes duration, despite unchanged fasting glycemia and tissuespecific insulin sensitivity [4,98].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Trials in people with T2D (not all with MASLD and some excluding high ALT values) have shown a moderate reduction in liver lipid content with empagli fl ozin, 414,415 dapagli fl ozin 416 and licoglifl ozin.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [415]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
A short questionnaire for the measurement of habitual physical activity in epidemiological studies
Baecke, J., Burema, J., & Frijters, J. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.936 · Cited by 3,945
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 1×
“56% [21]) occurred in 5 (20%) of 25 patients in the EMPA group and 2 (8%) of 24 patients in the placebo group at 24 weeks.”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · cited 1×
“02) and relative decrease in LFC (222% [236, 27]; P 5 0.”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Cited by
Items 301–370 of 370
Butt, M. I., Puri, G., Berkman, K., Ryder, S. J., Knowles, J., Shahzad, M. A., Malik, M. A., Shalev, N., & Sexton, J. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem937 · Cited by 2
“Empagliflozin has also been shown to reduce liver fat content and improve liver transaminases [32-34].”
Sajad, Q., Khan, K. A., Khan, A. Z., Khan, D., Iqbal, J., & Mustafa, M. I. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i2.663 · Cited by 1
Was bedeuten die neuen Diabetessubgruppen für Menschen mit Fettlebererkrankung?
Schröder, B., & Roden, M. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00698-5 · Cited by 1
Self-citationA nátrium-glükóz-kotranszporter-2-gátlók a diabetes mellitus kezelésén túl
Szekeres, Z. J., Stolcz, T., & Szabados, E. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.5.372 · Cited by 2
“Ugyanakkor egyéb antidiabetikus gyógyszerek is kompenzatorikus módon növelhetik a ketontestek képződését, de az SGLT2-gátlók emellett fokozzák a lipolízist is, és korlátozhatják a trigliceridek felhalmozódását a szervekben (32).”
Diabetes und Gastroenterologie – Update 2021: Leber, Kolon und Pankreas bei Diabetes mellitus
Bojunga, J., & Beckerbauer, A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00780-6 · Cited by 1
Saatmann, N., & Zaharia, O. (2021) · Diabetes aktuell · doi:10.1055/a-1646-0208 · Cited by 1
Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie
Apostolopoulou, M., & Roden, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_20 · Cited by 1
Self-citationDyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_58 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502639 · Cited by 1
Schützen Östrogene Frauen vor der Fettleber?
KAHL, S., & Hohlfeld, T. (2020) · Diabetes aktuell · doi:10.1055/a-1113-2684
“[15] Kahl S, Gancheva S, Strassburger K et al.”
BackgroundSelf-citationNichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes: Management und Therapie
Pützer, J., & KAHL, S. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00649-0
Self-citationZaharia, O. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1247-1420
“Are Lifestyle Therapies Effective for NAFLD Treatment? Trends in endocrinology and metabolism: TEM 2019; 30: 701–709 [19] Kahl S, Gancheva S, Straßburger K et al.”
BackgroundDiabetes mellitus und Fettlebererkrankungen
Bojunga, J., & Geier, A. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00510-w
Birkenfeld, A. L., Stefan, N., & Roden, M. (2021) · Diabetes aktuell · doi:10.1055/a-1417-5784
“Diese Ergebnisse zeigten aber auch, dass EMPA unabhängig von der Gewichtsabnahme in der frühzeitigen Therapie der NAFLD bei T2D effektiv sind [10].”
BackgroundSelf-citationDiabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose
Bojunga, J., & Friedrich‐Rust, M. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00822-z
Around Australia – Chickens and Campylobacter
Templeton, J. M., Hewitson, J. M., Giffard, P. M., & Blackall, P. J. (2014)
KAHL, S. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1664-5206
Self-citationImproving flexibility in substrate metabolism: a pharmacological and lifestyle approach
Veelen, A. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20230125av
A metabolically healthy lifestyle: A matter of timing?
Andriessen, C. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230706ca
Schick, R., Birkenfeld, A. L., Roden, M., Ziegler, A., & Fröhlich, B. (2023) · Diabetes aktuell · doi:10.1055/a-2094-0690
“SGLT2-Hemmer senken auch das Körpergewicht und können – wie die EMLIFA-Studie des DZD gezeigt hat – zudem den Leberfettgehalt reduzieren [15].”
BackgroundSelf-citationBAJAJ, H. S. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.119
Von Diabetes bis Schlafapnoe: Nach welchen Adipositas-Komplikationen sollen wir suchen?
Laubner, K. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1847-2632
“[33] Kahl S, Gancheva S, Strassburger K et al.”
BackgroundDrapkina, O. M., Блохина, А. В., Borisova, A. L., Bukaeva, A. A., Voshev, D. V., Garbuzova, E. V., Dzhioeva, O. N., Drozdova, L. Y., Олеговна, Е. С., Ershova, A. I., et al. (2023) · doi:10.15829/ropniz-d95-2023
Gómez, B. B. (2023) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/65186
Ursachen, Klinik und Folgen der Insulinresistenz bei Typ-2-Diabetes
Xourafa, G., & Roden, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01155-3 · Cited by 1
Self-citationUsefulness of long-term administration of SGLT2 inhibitors in patients with MASLD and diabetes
Ishii, K., Kawanaka, M., Oda, S., Kimura, M., Kawada, M., Tanikawa, T., Urata, N., Nishino, K., Suehiro, M., Haruma, K., et al. (2024) · Kanzo · doi:10.2957/kanzo.65.111
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Возможности применения ингибитора натрий- глюкозного котранспортера 2-го типа
Агабабян, И. Р., & Джаббарова, Н. М. (2024) · Кардиология в Беларуси · doi:10.34883/pi.2024.16.4.011
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69 · Cited by 1
Deshmukh, N., Kalshetti, M. S., Patil, M., Nandanwar, M., & Sangle, G. V. (2025) · Drug Research · doi:10.1055/a-2557-8927
“In clinical studies, selective SGLT2 inhibitors have been shown to attenuate steatosis and fibrosis in NAFLD patients without diabetes and type 2 diabetic patients with or without NAFLD, including biopsy-confirmed NASH patients [12, 13, 21–23].”
Song, Y., Fang, R., & Yu, B. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04056-5
Yalçın, N., Özkan, A. E., Görgülügil, G. Z., & Koca, N. (2025) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1697213
Rafat, Z., Delpasand, K., & Roostaei, D. (2023) · Journal of Current Biomedical Reports · doi:10.61882/jcbior.4.2.234
Can Coffee Combat Fatty Liver? A Review of Emerging Evidence
El-Hack, M. E. A., Arif, M., Tufarelli, V., & Swelum, A. A. (2025) · Al-Mustaqbal Journal of Pharmaceutical and Medical Sciences · doi:10.62846/3006-5909.1028
(2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1599-6
(2025) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-025-1595-x
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Скрипник, І. М., Musabaev, E. I., Nersesov, A., Baka, O., Golubovska, O. A., Турғунпулатовна, Д. Л., Dzhumabaev, M., Duisenova, A., Каримов, М. М., Мухтархановна, Н. Н., et al. (2025) · Family medicine European practices · doi:10.30841/2786-720x.3.2025.339469
Sethi, B. K., Mehta, A., Dasgupta, A., Chawla, M. S., Deka, N., Agarwal, N., Mazumder, C., Ghosh, I., Gala, V., Muchhala, S., et al. (2025) · Cureus · doi:10.7759/cureus.99023
“Empagliflozin has shown potential in reducing liver fat and fibrosis by improving insulin sensitivity and inducing weight loss [27,28,44].”
Gohari, S., Ismail‐Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., & Gohari, S. (2023) · Figshare · doi:10.6084/m9.figshare.24630303
Yun, B., Oh, J., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102175
Umais, M., Imtiaz, H., Luqman, M. S., Anwar, S., Iftikhar, M. U., Maheshwari, K., Sara, Z. T., Naseem, N. U. H., Ibnath, F. A., Syed, A. R. S., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04493-4
Yalçın, N., Ertınmaz, A., Görgülügil, G. Z., & Koca, N. (2025) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
林, 子. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163891
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Self-citationRôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Selvaraj, H., Dawn, V. J., & JOSE, R. (2026) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2026v19i5.58664
Mpisa, S., & Soldera, J. (2026) · World Journal of Nephrology · doi:10.5527/wjn.121652
Guo, W., Li, W., Li, X., Shi, W., Yan, Y., Yan, T., Zhou, J., & Huang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1865769
Petrakis, V., Rafailidis, P. I., Grapsa, A., Sousanidou, A., Bougiouklou, T., Babaka, N., Panagopoulos, P., & Papazoglou, D. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2897-4761
Lebererkrankungen als Komplikation des Diabetes mellitus
KAHL, S., & Huttasch, M. (2026) · Info Diabetologie · doi:10.1007/s15034-026-5273-x
“Diese Reduktion scheint maßgeblich mit dem durch SGLT-2-Inhibitoren vermittelten, mode-raten Gewichtsverlust (ca. 2 bis 3 kg über einen Zeit-raum von 6 bis 12 Monaten), möglicherweise aber auch mit einem Anstieg des Fettgewebshormons Adiponektin im Blut zusammenzuhängen [11].”
Self-citationImpatto degli SGLT2i sulla MASLD in pazienti con diabete mellito tipo 2
Tahani, N., & Caprio, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01825-y
Gorban, V. V., Витальевна, Г. Е., & Kocherga, P. E. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-194
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
“In RCTs using changes in MRI-assessed liver triglyceride contents as the primary endpoint, SGLT2is have been shown to significantly reduce hepatic steatosis [198,199,200].”
Toffoli, B., Sirignano, M., Bonato, V., Fusaro, G., Russo, E., Velardi, V., Crocè, L. S., Fabris, B., Candido, R., & Bernardi, S. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02976-3
“For instance, in dedicated RCTs using non-invasive liver parameters as primary outcomes, SGLT2 inhibitors such as dapagliflozin, empagliflozin, or canagliflozin have been shown to significantly decrease hepatic steatosis [ 9, 10 ].”
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
Newsome, J. S. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466571
Caponio, D., Acucella, G. A., & Acucella, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02759-5 · Cited by 1
Farsi, F., Sarvi, D. G., Abbasi, M., & Hasani‐Ranjbar, S. (2026) · International Journal of Endocrinology · doi:10.1155/ije/5558442
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
Kitazawa, M., Katagiri, T., Suzuki, H., Yamada, M., Hatta, M., TAKIZAWA, H., Murai, K., Sato, T., Matsubayashi, Y., Yamada, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71211
“Indeed, randomised trials have demonstrated that SGLT2 inhibitors can improve hepatic fat content [21, 22] and the proposed mechanisms include reduced de novo lipogenesis, enhanced fatty acid oxidation and decreased hepatic glucose production [13].”
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716
“Zudem wurden MRT-PDFF, für Dapagliflozin (n=32) und Empagliflozin (n=84) beschrieben [68, 69].”
Kim, S., Ko, H. Y., Hong, B., Kim, J., Bea, S., Bae, J. H., Cho, Y. M., Chang, Y., Byrne, C. D., & Shin, J. (2026) · Diabetologia · doi:10.1007/s00125-026-06870-8
Endocrine determinants of MASLD: mechanisms and therapeutic targets
Chaturvedi, R., Mathew, A., Pradhan, A., Goyal, M., Sharma, M., Kachroo, V., Agrawal, C., Krishnamurthy, A., Atreja, S. M., & Atreja, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1967494
Shieh, M., Dalil, D., Arefzadeh, A., & Shiehmorteza, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70484
Ding, Y., Ma, X., Luo, Y., Zhou, Z., Li, L., Ge, Z., & Ji, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.2005171
Metadata
- Authors
- Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., Kantartzis, K., Kupriyanova, Y., Markgraf, D., van Gemert, T., Knebel, B., Wolkersdorfer, M. F., Kuss, O., Hwang, J.-H., Bornstein, S. R., Kasperk, C., Stefan, N., Pfeiffer, A., Birkenfeld, A. L., & Roden, M.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- GWT-TUD GmbH (Germany) (DE)
- University Hospital Heidelberg (DE)
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- Landesapotheke Salzburg, Salzburg, Austria
- Paul Langerhans Institute Dresden (DE)
- Corresponding author
- Roden, Michael
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-20
- Volume
- 43
- Issue
- 2
- Pages
- 298-305
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2973671909
- Semantic Scholar
- d30e2aeb028f87844806b2c67eeca77b51e7e36a
- Cited by
- 360
- References
- 43
- Citations by year
- 2026: 47 · 2025: 59 · 2024: 58 · 2023: 59 · 2022: 54 · 2021: 46 · 2020: 35 · 2019: 1
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- German Diabetes Center
- German Federal Ministry of Health
- German Center for Diabetes Research
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, liver fat, hepatic steatosis, non-alcoholic fatty liver disease, insulin sensitivity, uric acid, high molecular weight adiponectin, weight loss, glycemic control, recent-onset diabetes, isotope dilution
- MeSH terms
- Adipose Tissue, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Germany, Glucosides, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Placebos, Weight Loss, Down-Regulation, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.